Array stock: buy or sell?
July 30th, 2019
Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific.
Should I buy Array stock?You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. Following a trading strategy helps to make decisions easier, quicker and with less hesitations. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
Currently, 2 buy setups are elegible for Array stock now:
|New all-time high||Yes|
|New 52 week high||Yes|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Array BioPharma stock a buy?
Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we collected 15 ratings published for ARRY stock in the last month.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-7-12||JPMorgan Chase & Co.||Overweight||Neutral|
|2019-6-18||Svb Leerink||Outperform||Market Perform|
|2019-6-18||Leerink Swann||Outperform||Market Perform|
|2019-6-18||Goldman Sachs Group||n/a||Neutral|
|2019-6-17||Wells Fargo & Co||Outperform||Market Perform|
|2019-6-17||Piper Jaffray Companies||Overweight||Neutral|
|2019-6-17||Jefferies Financial Group||Buy||Hold|
|2019-5-21||Piper Jaffray Companies||n/a||Overweight|
|2019-3-14||JPMorgan Chase & Co.||Positive||Overweight|
|2019-1-15||Piper Jaffray Companies||Overweight||Positive|
Array stock analysis
After several days of continuous hikes in past weeks, Array remained steady 0.00% to $47.85.
After reaching all time highs on July, Array BioPharma remained constant 0.00% to $47.85. ARRY broke out again over $47.01 after a 1.68% correction started on July. On May ARRY price bounced up over the SMA of 100 days demonstrating to be a significant support for this stock. On July, ARRY hit a new all time high, pushing higher than on July tops. Check different trading setups that use ATHs as triggers.
Array shares peaked new all time highs back again this week, marking to $47.98. Shares ended at $47.85 and gained 1.18% during the week. By mid June ARRY skyrocketed an astounding 35.95% in just one week.
Price pattern shows an uptrend with two rising tops and bottoms, and now finally trading above the $47.05 resistance. Since SMA20d and SMA40w crossed up early February, ARRY price climbed $28.65 per share (149.22%). Late December 2018 ARRY price bounced up over the SMA of 40 weeks that acted as support stopping new slides.
Array stock price history
Array IPO was on November 30th, 2000 at $8.75 per share1. Since then, ARRY stock grew a 446.90%, with an average of 24.80% per year. If you had invested $1,000 in Array stock in 2000, it would worth $4,469.00 today.
1: Adjusted price after possible price splits or reverse-splits.
Array stock historical price chart
ARRY stock reached all-time highs on July with a price of $47.98.
Array stock price target is $36.80How much a stock will be priced tomorrow or next week is quite unpredictable However, many stock price predictions are published every day by banks, financial institutions and independent analysts. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last 30 days we found 9 price forecasts for Array stock:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-7-12||JPMorgan Chase & Co.||Downgrades||$29.00||$48.00||65.5%|
|2019-6-18||Goldman Sachs Group||Raises Target||$27.00||$38.00||40.7%|
|2019-5-22||SunTrust Banks||Raises Target||n/a||$32.00||-|
|2019-5-21||Piper Jaffray Companies||Reiterates||$28.00||$35.00||25%|
|2019-3-14||JPMorgan Chase & Co.||Reiterates||$18.00||$29.00||61.1%|
|2019-1-15||Piper Jaffray Companies||Reiterates||n/a||$28.00||-|
Financials and fundamental analysis
Earnings date and Earnings per ShareArray let down analysts on February when it reported an Earnings per Share (EPS) of $-0.05 when the market consensus was $-0.16.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, Array BioPharma annual revenues rocketed an extraordinary 15.19% to $173.77 M dollars from $150.85 marked in 2017. In contrary, its profit margin (compared to sales) dropped to -84.79%, that is $-147.35 million. To have an up to date view of the financial situation of Array, we have calculated the trailing twelve month (TTM) sales and income figures. TTM values are the sum of the last 4 quarters and aproximate to an annual fiscal report ending in 2018-Q4 that can be compared to 2018 fiscal year results. Annual Array TTM sales up to December 2018 were $241.26 and income was $-111.47 million dollars. When comparing this TTM figures with the last reported annuality, we can review Array BioPharma business evolution since June 2018: Annual sales up to December, compared to lastest yearly report, boosted an amazing 38.84%. In line, profit margin (net income/revenues) climbed at -84.79%.
|2013||$70 M||-||$-61.94 M-89.0%||-|
|2014||$42 M||-39.52%||$-85.26 M-202.6%||37.65%|
|2015||$52 M||23.36%||$9.37 M18.0%||-110.99%|
|2016||$138 M||165.62%||$-92.84 M-67.3%||-1,090.93%|
|2017||$151 M||9.41%||$-116.82 M-77.4%||25.83%|
|2018||$174 M||15.19%||$-147.35 M-84.8%||26.13%|
|TTM||$241 M||38.84%||$-111.47 M-46.2%||-24.35%|
Quarterly financial resultsArray reported $82.55 million in sales for 2018-Q4, a 45.05% up compared to previous quarter. Reported quarter earnings marked $-11.36 M with a profit margin of -13.76%. Profit margin skyrocketed a 29.83% compared to previous quarter when profit margin was -43.60%. When comparing revenues to same quarter last year, Array BioPharma sales marked an exceptional increase and climbed a 95.53%. Looking back to recent quarterly results, Array posted 2 positive quarters in a row.
|2017-Q1||$33 M||-||$-35.32 M-106.1%||-|
|2017-Q2||$34 M||1.50%||$-29.59 M-87.6%||-16.22%|
|2017-Q3||$30 M||-11.94%||$-37.99 M-127.7%||28.40%|
|2017-Q4||$42 M||41.93%||$-34.05 M-80.7%||-10.37%|
|2018-Q1||$66 M||57.20%||$-22.85 M-34.4%||-32.90%|
|2018-Q2||$35 M||-46.60%||$-52.45 M-148.0%||129.52%|
|2018-Q3||$57 M||60.59%||$-24.81 M-43.6%||-52.69%|
|2018-Q4||$83 M||45.05%||$-11.36 M-13.8%||-54.21%|
Array ownershipWhen you are planning to buy a stock, it's worth to review its ownership structure.
Array shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a of all shares.
The following table compares ownership indicators for other stocks related to Array:
|Market cap||$0.0 M|
|Total shares||0.0 M|
|Float shares||0.0 M|
|- Institutional holdings (%)||0.0%|
|- Insider holdings (%)||0.0%|
|Shares in short selling||0.0%|
|Tuesday, July 30th, 2019|
|Day range||$47.84 - $47.98|
|Average true range||$0.38|
|50d mov avg||$39.37|
|100d mov avg||$31.28|
|200d mov avg||$24.31|
Array performanceStocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. In the following table, we compare Array BioPharma performance to :